This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): P-680
Description: GS9411 increases airway hydration for the treatment of pulmonary disease. Previously known as P-680, GS9411 is an acylguanidine analog of amiloride that blocks the epithelial sodium channel (ENaC). It was designed to avoid building up of calcium in the kidneys, which can be caused by blocking that channel.
Deal Structure: In August 2007, Parion Sciences and Gilead Sciences announced that they entered into an exclusive licensing and co-development agreement focused on P-680. The agreement grants Gilead worldwide commercialization rights to P-680 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and non-CF bronchiectasis. In addition, the companies will collaborate on a research program to identify other promising ENaC blocker-based drug candidates utilizing Parion's proprietary ENaC-based chemistry platform.
According to the terms of the agreement, Gilead will provide an upfront payment of $5 million for the license and make an additional $5 million investment in Parion. In addition, under the license, Gilead will supply research funding and may make payments upon achievements of certain milestones resulting in a potential deal value of approximately $146 million. Parion will perform the IND-enabling studies for P-680 and will...See full deal structure in Biomedtracker
Partners: Parion Sciences, Inc.
GS 9411 News
Pink Sheet Chart: Weekly Trademark Review
Additional information available to subscribers only: